Drug Profile
IDP 107
Alternative Names: IDP-107Latest Information Update: 02 Aug 2017
Price :
$50
*
At a glance
- Originator Dow Pharmaceutical Sciences
- Class Antiacnes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acne vulgaris
Most Recent Events
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 06 Feb 2012 Dow Pharmaceutical Sciences completes a phase II trial in Acne vulgaris in USA and Canada (NCT01194375)
- 03 Nov 2011 Dow Pharmaceutical Sciences completes enrolment in a phase II trial in Acne vulgaris in USA and Canada (NCT01194375)